Treatment of Inflammatory Macular Edema with Humanized Anti-CD11a Antibody Therapy

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6919-6924

  Faia, Lisa J ^a,b   Nida Sen, H ^a   Li, Zhuqing ^a   Yeh, Steven ^a,c   Wroblewski, Keith J ^a,d   Nussenblatt, Robert B ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b ASSOCIATED RETINAL CONSULTANTS   (United States)

^c CASEY EYE INSTITUTE   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CYCLOSPORIN; EFALIZUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; MONOCLONAL ANTIBODY; NCAM1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL COUNT; CLINICAL ARTICLE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EYE DISCOMFORT; EYE PAIN; FATIGUE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEADACHE; HOT FLUSH; HUMAN; LYMPHOCYTOSIS; MALE; NATURAL KILLER CELL; NAUSEA; NEUTROPENIA; OPEN STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RETINA MACULA EDEMA; RETINA MACULA LUTEA; SORE THROAT; VISUAL ACUITY; VISUAL IMPAIRMENT; CLINICAL TRIAL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; UVEITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; ANTIGENS, CD56; FEMALE; FLOW CYTOMETRY; HUMANS; INJECTIONS, SUBCUTANEOUS; KILLER CELLS, NATURAL; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

EID: 80054869550     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5896     Document Type: Article

References (25)

1. Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113:1446-1449.
2. Jabs DA, Rosenbaum JT. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2001;131(5):679.
3. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492-513.
4. Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol. 2008;146(6):802-812, e1.
5. Raptiva package insert. South San Francisco, CA: Genentech, Inc.; 2009.
6. Gottlieb AB, Krueger JG, Wittkowski K, Dendrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol. 2002;138(5): 591-600.
7. Whitcup SM, DeBarge LR, Caspi RR, Harning R, Nussenblatt RB, Chan CC. Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol. 1993;67(2):143-150.
8. Whitcup SM, Hikita N, Shirao M, et al. Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis. Exp Eye Res. 1995;60(6):597-601.
9. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003;49(2 suppl):S98-S104.
10. Efalizumab (Raptiva) for treatment of psoriasis. Med Lett Drugs Ther. 2003;45(1171):97-98.
11. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290(23):3073-3080.
12. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003; 349(21):2004-2013.
13. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421-2438.
14. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986;136:4480-4486.
15. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633-640.
16. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol. 1989;143:3183-3191.
17. Campbell JJ, Qin S, Unutmaz D, et al. Unique subpopulations of CD56_NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol. 2001;166: 6477-6482.
18. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood. 2001;97:3146-3151.
19. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin-2. J Clin Invest. 1993;91:123-132.
20. Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol. 2005;174(9):5187-5191.
21. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2R alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006;11;103(15):5941-5946.
22. Common Toxicity Criteria. Frederick, MD: National Cancer Institute, the National Institutes of Health; 2009. http://ctep.cancer.gov/ protocoldevelopment/electronic_applications/ctc.htm#ctc_mapping_ docs.
23. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73-79.
24. Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull. 2008;31(8):1541-1546.
25. Cellcept package insert. South San Francisco, CA: Genentech, Inc.; 2010.